simmitinib
Phase 2Small molecule
simmitinib is one of 76 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.
2
Indications
5
Total Trials
4
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
241 competitors in Esophageal Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Imfinzi
AstraZenecaPhase 3
Eloxatin
TevaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tecentriq
RochePhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Bayer Aspirin
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Esophageal Squamous Cell Carcinoma2 trials
Advanced Solid Tumors2 trials
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06132217·168 enrolled
Gastroesophageal Junction Adenocarcinoma1 trial
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06577376·252 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for simmitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details